When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type?
- 22 October 2009
- journal article
- research article
- Published by Elsevier BV in Annals Of Oncology
- Vol. 21 (5), 1058-1063
- https://doi.org/10.1093/annonc/mdp412
Abstract
Background: The incidence and risk factors of central nervous system (CNS) invasion is still unclear in extranodal natural killer (NK)/T-cell lymphoma, nasal type. Patients and methods: We analyzed 208 patients to study the clinical features and outcomes of CNS disease in extranodal NK/T-cell lymphoma. Results: Twelve patients (5.76%, 12/208) experienced CNS disease during treatment or follow-up period (median 11.62 months, range 0.2–123.2 months). The clinical variables associated with CNS disease were Ann Arbor stage III/IV (15.87%, P P = 0.006), group III/IV of NK/T-cell lymphoma prognostic index (NKPI; 10.20%, P = 0.003), high/high–intermediate international prognostic index (9.30%, P = 0.072) and extra-upper aerodigestive primary sites (9.75%, P = 0.008). In multivariate analysis, NKPI retained the strongest statistical power to predict CNS disease (P = 0.007, relative risk 9.289, 95% confidence interval 1.828–47.212) in extranodal NK/T-cell lymphoma. Conclusions: Despite extranodal NK/T-cell lymphoma frequently involves paranasal sinus, a routine CNS evaluation and prophylaxis do not seem to be necessary in NKPI group I or II patients due to a very low incidence. Nevertheless, CNS prophylaxis should be considered in NKPI groups III and IV.Keywords
This publication has 25 references indexed in Scilit:
- Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisoloneAnnals Of Oncology, 2008
- Phase I study of dexamethasone, methotrexate, ifosfamide, l‐asparaginase, and etoposide (SMILE) chemotherapy for advanced‐stage, relapsed or refractory extranodal natural killer (NK)/T‐cell lymphoma and leukemiaCancer Science, 2008
- Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: A Prognostic Model From a Retrospective Multicenter StudyJournal of Clinical Oncology, 2006
- Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxisLeukemia & Lymphoma, 2005
- Primary diffuse large B-cell non-Hodgkin lymphoma of the paranasal sinuses: a report of 14 casesBritish Journal of Haematology, 2005
- Extranodal nasal type NK/T-cell Lymphoma: Elucidating clinical prognostic factors for risk-based stratification of therapyEuropean Journal Of Cancer, 2005
- Clinical relevance of three subtypes of primary sinonasal lymphoma characterized by immunophenotypic analysisHead & Neck, 2004
- Sinonasal LymphomaThe American Journal of Surgical Pathology, 1999
- Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients.Journal of Clinical Oncology, 1998
- Nation‐wide study of lethal mid‐line granuloma in Japan: Frequencies of Wegener's granulomatosis, polymorphic reticulosis, malignant lymphoma and other related conditionsInternational Journal of Cancer, 1989